Skip to Content
 

News: Translational Research and Interventional Oncology Research Program

New prostate cancer treatment concept

Friday, August 30th, 2019

Combining immunotherapy and radiation therapy may be a powerful treatment approach for castration-resistant prostate cancer.

Grant bolsters research on myelodysplastic syndromes

Friday, August 9th, 2019

Michael Savona, MD, professor of Medicine and Cancer Biology, and director of Hematology Research at Vanderbilt-Ingram Cancer Center, has received a competitive grant award from the Edward P. Evans Foundation.

Encephalitis identified as rare toxicity of immunotherapy treatment

Monday, July 22nd, 2019

Researchers are chronicling rare but serious toxicities that may occur with immune checkpoint inhibitors, the most widely prescribed class of immunotherapies.

Childhood cancer: how it’s different than for adults

Saturday, June 29th, 2019

The nature of childhood cancer is different than adult cancer, and so is the approach to treatment.

Cardiac toxicity risk factors identified with relapsed multiple myeloma therapy

Saturday, June 29th, 2019

More than half of patients with relapsed multiple myeloma treated with carfilzomib experienced cardiac issues during treatment, according to a multi-institutional study published June 12 in the Journal of Clinical Oncology.

Treatment approved for patients with acute graft-versus-host disease

Saturday, June 29th, 2019

The U.S. Food and Drug Administration (FDA) recently approved ruxolitinib, the first drug for patients with acute graft-versus-host disease (GVHD) who have an inadequate response to steroid treatment.

Immunotherapy helping 87-year-old man stay on the job

Friday, June 7th, 2019

Immunotherapy is helping cancer patient Roszell Mack Jr. to continue going to his job on a Kentucky horse farm.

Pathways of radiosensitization

Thursday, April 25th, 2019

Austin Kirschner, MD, PhD, and colleagues have studied the mechanism of radiation sensitization for enzalutamide using multiple models of human prostate cancer.

Study reframes approach to targeted therapy resistance

Thursday, April 25th, 2019

A recent study provides clinicians genomic guidance for surveillance of targeted therapy resistance in patients with EGFR-mutant non-small cell lung cancer — and more importantly — another drug option when resistance occurs.

Achilles’ heel for kidney cancer

Monday, March 4th, 2019

A recent study found that renal cell carcinoma cells with mutations in an enzyme-encoding gene, SETD2, were sensitive to a drug that inhibits the enzyme PI3K-beta.

Next Page »